Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Вторник, 21 октября 2008 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Теветен
Регистрация
Телеконференция «Управление сосудистым риском при сахарном диабете 2 типа. Новые возможности максимальной сосудистой защиты»
Новая вакансия

Библиография

Включен в программу ОНЛС

  1. Petersen S,Rayner M.Coronar y heart disease statistics 2002 edition.British Hear t Foundation Statistics Database Annual Compendium
  2. Williams B,Poulter NR,Brown MJ, et al.Guidelines for management of hyper tension:repor t of the four th working par t y of the British Hyper tension Societ y,2004 -BHS IV.J Hum Hyper tens 2004;18:139-185
  3. Burn J,Dennis M,Bamford J,et al. Long-term risk of recurrent stroke af ter a first-ever stroke:the Oxfordshire Communit y Stroke Project.Stroke 1994;25:333-337
  4. Stamler J,Stamler R,Neaton JD.Blood pressure, systolic and diastolic,and cardiovascular risks:US population data. Arch Intern Med 1993;153:598-615
  5. Sega R,on behalf of the Eprosar tan Study Group.Ef ficacy and safet y of eprosar tan in severe hyper tension.Blood Pressure 1999;8:114-121
  6. Schrader J,Luders S,Kulschewski A,et al.Morbidit y and mor talit y af ter stroke, eposar tan compared with nitrendipine for secondar y prevention.Stroke 2005;36: (In Press).Additional information cited for the MOSES study was presented at the ESC,Munich,2004/data on file
  7. Gavras I,Gavras H.Safet y and tolerabilit y of eprosar tan. Pharmacotherapy 1999;19 (4 Pt 2):102S-107S
  8. Elliott WJ,for the Eprosar tan Study Group.Double-blind comparison of eprosar tan and enalapril on cough and blood pressure in unselected hyper tensive patients.J Hum Hyper tens 1999;13: 413-417
  9. Oparil S.Eprosar tan versus enalapril in hyper tensive patients with angiotensin conver ting enzyme inhibitor-induced cough.Curr Ther Res 1999;60 (1):1-14
  10. Ohlstein EH,Brooks DP,Feuerstein GZ,Ruf folo RR.Inhibition of sympathetic outflow by the angiotensin II receptor antagonist,eprosar tan,but not by losar tan,valsar tan or irbesar tan: relationship to dif ferences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55(5):244-251
  11. Balt JC,Mathy MJ,Pfaf fendorf M,et al.Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor ef fects in the pithed rat:comparison bet ween valsar tan,candesar tan,eprosar tan and embusar tan.J Hyper tens 2001;19:2241-2250
  12. McInnes G.Pocket reference to angiotensin II antagonists.Science Press 1998
  13. Swales JD.Current status of hyper tensive disease treatment:results from the Evaluation and Inter ventions for Systolic Blood pressure Elevation: Regional and Global (EISBERG)project. J Hyper tens 1999;17(suppl2):S15-S19
  14. Chobanian AV,Bakris GL,Black HR, et al.The seventh repor t of the Joint National Committee on prevention, detection,evaluation,and treatment of high blood pressure:the JNC 7 repor t. JAMA 2003;289:2560-2572
  15. ESH Guidelines Committee.2003 European Societ y of Hyper tension – European Societ y of Cardiology guidelines for the management of ar terial hyper tension.J Hyper tens 2003;21(6): 1011-1053
  16. Brooks DP,Ruf folo RR. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.J Hyper tens 1999;17(Suppl 2):S27-S32
  17. Franklin SS,Gustin W,Wong ND,et al.Hemodynamic patterns of age-related changes in blood pressure.Circulation 1997;96:308-315
  18. Kannel W.Prevalence and implications of uncontrolled systolic hyper tension.Drugs Aging 2003;20: 277-286
  19. SHEP Cooperative Research Group. Prevention of stroke by antihyper tensive drug treatment in older persons with isolated systolic hyper tension:final results of the Systolic Hyper tension in the Elderly Program (SHEP).JAMA 1991;265: 3255-3264
  20. Staessen JA,Fagard R,Thijs L,et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hyper tension.Lancet 1997;350:757-764
  21. London GM,Guerin A.Influence of ar terial pulse and reflective waves on systolic blood pressure and cardiac function.J Hyper tens 1999;17(Suppl 2): S3-S6
  22. Ziogas J,Cunnane TC.An electro-physiological study of the actions of angiotensin II at the sympathetic neuroef fector junction in the guinea pig vas deferens.Br J Pharmacol 1991;103: 1196-1202
  23. Tsuda K,Tsuda S,Ura M,et al. Inhibitor y actions of captopril on norepinephrine release from adrenergic ner ve endings in spontaneously hyper tensive rats.Jpn Hear t J 1988;29: 475-483
  24. Kannel WB.Dawber TR,Kagan A,et al.Factors of risk in the development of coronar y hear t disease -six year follow-up experience.The Framingham Study. Ann Intern Med 1961;55:33-50
  25. Messerli F.Antihyper tensives and stroke reduction.In:Repor t from the satellite symposium held at X XVI Congress of the European Societ y of Cardiology,Munich,30 August 2004
  26. Medical Research Council Working Par t y.MRC trial of mild hyper tension: principal results.BMJ 1985;291:97-104
  27. MRC Working Par t y.Medical research Council trial of treatment of hyper tension in older adults:principal results.BMJ 1992;304:405- 413
  28. The Dutch TIA trial study group. Trial of secondar y prevention with atenolol af ter transient ischemic attack or nondisabling ischemic stroke.Stroke 1993;24:543-548
  29. Eriksson S,Olofsson B-O,Wester B-O,for the TEST study group.Atenolol in secondar y prevention af ter stroke. Cerebrovasc Dis 1995;5:21-25
  30. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure- lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.Lancet 2001;358:1033-1041
  31. DahlЪf B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidit y and mor talit y in the Losar tan Inter vention for Endpoint reduction in hyper tension study (LIFE):a randomized trial against atenolol.Lancet 2002;359:995-1003
  32. Lithell H,Hansson L,Skoog I,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double- blind trial. J Hyper tens 2003;21:875-886
  33. Julius S,Kjeldsen SE,Weber M,et al.Outcomes in hyper tensive patients at high cardiovascular risk treated with regimens based on valsar tan or amlodipine:the VALUE randomised trial. Lancet 2004;363:2022-2031
  34. Kulber tus H.Clinical study of the month.The CHARM study.Rev Med Liege 2003;58 (10):646- 652
  35. Program for irbesar tan mor talit y and morbidit y evaluations (PRIME).Data on file.
  36. Ram V.Eprosar tan -a unique therapeutic profile. In:Repor t from the satellite symposium held at X XVI Congress of the European Societ y of Cardiology,Munich,30 August 2004
  37. Edwards RM,Aiyer N,Chilstein EH, et al.Pharmacological characterisation of the nonpeptide angiotensin II receptor antagonist SK&F; 108566.J Pharmacol Exp Ther 1992;260:175-181
  38. Hollenberg NK.Introduction. Pharmacotherapy 1999;19 (4 Pt 2):71S- 72S
  39. Ilson B.Drug interaction studies with eprosar tan,a novel angiotensin II receptor antagonist.Am J Hyper tens 1998;11(4 Pt 2):108A (Abstract E051)
  40. Christensen M,Ibsen H,Worck R. Ef fect of eprosar tan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypo-glycaemia.Clin Sci 2005;108:113-119
  41. Ruilope L,Jager B,Prichard,B. Eprosar tan versus enalapril in elderly patients with hyper tension:a double-blind,randomized trial.Blood Pressure 2001;10:223-229
  42. Punzi HA,Punzi CF,et al.Once-daily eprosar tan mesylate in the treatment of elderly patients with isolated systolic hyper tension:data from a 13-week double-blind,placebo-controlled, parallel, multicenter study.J Human Hyper tens 2004:1-7
  43. Teitelbaum I,Chilvers M,Reiz RJS.The angiotensin receptor blocker eprosar tan mesylate reduces pulse pressure in isolated systolic hyper tension. Can J Cardiol 2004;20 (Suppl C):11C-16C
  44. Vaccarino V,Berger AK,Abramson J,et al.Pulse pressure and risk of cardiovascular events in the Systolic Hyper tension in the Elderly Program. Am J Cardiol 2001;88:980-986
  45. Franklin S,Khan S,Wong N,et al.Is pulse pressure useful in predicting risk for coronar y hear t disease? The Framingham Hear t Study.Circulation 1999;100:354-360
  46. de la Sierra A,Munoz A,Arcos E,et al.The ef fect of treatment with eprosar tan on pulse pressure: factors predicting response.Can J Cardiol 2004;20 (Suppl C):17C-22C
  47. de la Sierra A,Munoz A,Arcos E,et al.Ef fect of eprosar tan on pulse pressure and blood pressure components in patients with isolated systolic hyper tension.Blood Pressure 2004;13(Suppl 2):5-10
  48. Robles NR,Mar tin-Agueda B,Lopez-Munoz F,et al.Ef fectiveness and safet y of eprosar tan on pulse pressure for the treatment of hyper tensive patients.Int J Clin Pract 2005;59 (4):478- 484
  49. Puig JG,Mateos F,Buno A,et al. Ef fect of eprosar tan and losar tan on uric acid metabolism in patients with essential hyper tension.J Hyper tens 1999;17:1033-1039
  50. Hedner T,Himmelmann A,for the Eprosar tan Multinational Study Group. The ef ficacy and tolerance of one or t wo daily doses of eprosar tan in essential hyper tension.J Hyper tens 1999;17(1): 129-136
  51. Gradman AH,Gray J,Maggiacomo F,et al.Assessment of once-daily eprosar tan,an angiotensin II antagonist, in patients with systemic hyper tension. Clin Ther 1999;21:442-453
  52. Argenziano L,Trimarco B.Ef fect of eprosar tan and enalapril in the treatment of elderly hyper tensive patients: Subgroup analysis of a 26- week,double- blind,multicentre study.Curr Med Res Opin 1999;15(1):9-14
  53. Levine B.Ef fect of eprosar tan and enalapril in the treatment of black hyper tensive patients:subgroup analysis of a 26-week,doubleblind, multicentre study.Curr Med Res Opin 1999;15:25-32
  54. Levine B.Eprosar tan provides safe and ef fective long-term maintenance of blood pressure control in patients with mild to moderate essential hyper tension. Curr Med Res Opin 2001;17(1):8-17
  55. Sachse A,Verboom CN,JКger B. Ef ficacy of eprosar tan in combination with HCTZ in patients with essential hyper tension.J Hum Hyper tens 2002;16: 169-176
  56. Lees KR,Bath PMW,Naylor AR. Secondar y prevention of transient ischaemic attack and stroke.BMJ 2000;320:991-994
  57. Hankey GJ,Warlow CP.Treatment and secondar y prevention of stroke:evidence, costs,and ef fects on individuals and populations.Lancet 1999;354:1457-1463
  58. Straus SE,Majumdar SR,McAlister FA.New evidence for stroke prevention. JAMA 2002;288:1388-1395
  59. Labios M,Mar tinez M,Gabriel F,et al.Ef fect of eprosar tan on cytoplasmic free calcium mobilization, platelet activation,and micropar ticle formation in hyper tension.Am J Hyper tens 2004;17(9):757-763
  60. Makris TK,Stavroulakis G, Papadopoulos DP,et al.Eprosar tan ef fect on fibrinolytic/haemostatic variables in ar terial hyper tension:a comparative study to losar tan.Drugs Exptl Clin Res 2004;30 (3):125-132
  61. Neumann J,Ligtenberg G,Oey L,et al.Moxonidine normalizes sympathetic hyperactivit y in patients with eprosar tan-treated chronic renal failure.J Am Soc Nephrol 2004;15:2902- 2907
  62. Koomans HA,Blankestijn PJ,Joles JA. Sympathetic hyperactivit y in chronic renal failure: A wake-up call.J Am Soc Nephrol 2004;15:524-537
  63. Frank H,Schobel H-P,Vitkowsky J, et al.Ef fects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress.Kidney Int 2003;63:617-623
  64. Eprosar tan Periodic Safet y Update, Data on file,Solvay Pharmaceuticals
  65. Eprosar tan Summar y of Product Characteristics (master)
  66. Harland D,Duf f D,Laing S,et al. Safet y of eprosar tan in elderly patients with hyper tension. Am J Hyper tens 1998; 11:78A (Abstract D039)
  67. Goodfriend TL,Elliott ME,Catt KJ.Angiotensin receptors and their antagonists.N Engl J Med 1996;334: 1649-1654
  68. Nakashima M,Uematsu T,Kosuge K, Kanamaru M.Pilot study of the uricosuric ef fect of DuP-753,a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335
  69. Burnier M,Hogman M,Nussberg J,et al.Shor t-term and sustained renal ef fects of angiotensin II receptor blockade in healthy subjects.Hyper tension 995;25: 602-609
  70. BЪhm M,Sachse A.Safet y and tolerabilit y of eprosar tan in combination with hydrochlorothiazide. Drug Safet y 2002;25(8):599-511
  71. Tenero D,Mar tin D,Ilson B,et al. Pharmacokinetics of intravenously and orally administered eprosar tan in healthy males:absolute bioavailabilit y and ef fect of food.Biopharm Drug Dispos 1998;19: 351-356
  72. Chapelsky MC,Mar tin DE,Tenero DM,et al.A dose propor tionalit y study of eprosar tan in healthy male volunteers. J Clin Pharmacol 1998;38:34-39
  73. Tenero DM,Mar tin DE,Miller AK, et al.Ef fect of age and gender on the pharmacokinetics of eprosar tan.Br J Clin Pharmacol 1998;46:267- 270
  74. Tenero D,Mar tin D,Chapelsky M, et al.Ef fect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosar tan.Pharmacotherapy 1998;18 (1):42-50
  75. Tenero D,Mar tin D,Chapelsky M, et al.Ef fect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosar tan.Pharmacotherapy 1998;18 (1):42-50
  76. Cox PJ,Bush BD,Gor ycki PD,et al.The metabolic fate of eprosar tan in healthy subjects.Exp Toxic Pathol 1996; 48 (Suppl II ):75-82
  77. Mar tin DE,Tompson D,Boike SC,et al.Lack of ef fect of eprosar tan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.Br J Clin Pharmacol 1997;43: 661-664
  78. Kovacs S,Mar tin DE,Ilson B,et al. An evaluation of the pharmacokinetics of a single oral dose of eprosar tan in hemodialysis-dependent patients with end stage renal disease compared to volunteers with normal renal function. Pharmacotherapy 1998;19:612-619



Solvay Pharma Реклама: Вестибулярные растройства. Информация для специалистов
Баннерная сеть Солвей-Фарма.ру
Адрес


Последнее обновление  21.10.2008 г.